Global and Chinese Monoclonal Antibody Industry Report
DUBLIN, March 25, 2014 /PRNewswire/ –
Research and Markets (http://www.researchandmarkets.com/research/q29sqz/global_and
) has announced the addition of the “Global and Chinese Monoclonal Antibody Industry
Report” [http://www.researchandmarkets.com/research/q29sqz/global_and ] report to their
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Currently, monoclonal antibody agents have been successfully used in the treatment of
tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical
industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of
13%, far higher than the overall growth rate of biopharmaceuticals in the same period.
Thanks to robust market demand, approval of new products and new indications as well as
launch of monoclonal antibody generic drugs, the global monoclonal antibody market size
will ascend by more than 12% in 2013-2017, hitting USD141 billion in 2017.
Driven by enhanced economic level, expanded scope of medical insurance reimbursement,
as well as lower prices incurred by intensified competition, Chinese monoclonal antibody
market is expected to continue to grow significantly. In 2013-2017, Chinese monoclonal
antibody market will grow at 35%, sharing 21.5% of the global monoclonal antibody market
in 2017 (9.5% in 2012).
The global monoclonal antibody industry is still dominated by European and American
companies, especially, important monoclonal antibody products are mainly produced by Roche
(Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson and other companies. In 2012, the
global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab
(Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzumab (Roche) stemmed from the
above four companies. The global sales (including the sales of third parties) of these six
monoclonal antibody agents totaled USD45 billion, accounting for 57.7% of the global.
Propelled by the optimistic market prospect, advancement of monoclonal antibody
technologies and the upcoming patent expiration of several key monoclonal antibody agents,
the research and industrialization of monoclonal antibody agents has become a global
investment highlight, wherein the future market competition will be evident.
In September 2013, the Infliximab generic drug – Inflectra developed by South Korea
Celltrion and the U.S. Hospira jointly was launched upon the approval of the EU EMA. In
November 2013, the Trastuzumab generic drug developed by the U.S. Mylan and India Biocon
together was available in the market under the permit of Drug Controller General Of India.
Mylan will sell the product tagged with the brand name Hertraz in India in early 2014.
In addition, India Biocon’s first anti-CD6 Alzumab (Itolizumab) for the treatment of
chronic plaque psoriasis was approved to be sold in India in August 2013.
Key Topics Covered:
1 Overview of Monoclonal Antibody Industry
2 Overview of Global Monoclonal Antibody Industry
3 Chinese Monoclonal Antibody Market
4 Key Foreign Monoclonal Antibody Agent Enterprises
5 Key Chinese Monoclonal Antibody Agent Enterprises
6 Summary and Forecast
- AbbVie - Amgen - Beijing Biotech Pharmaceutical Co., Ltd. - Beijing SL Pharmaceutical Co., Ltd. - Chengdu Huasun Group Co., Ltd. - Huahai Pharmaceutical Co., Ltd. - Johnson & Johnson - Merck - NVS - Roche Pharmaceuticals - Shanghai CP GuoJian Biotech Academy - Shanghai CP Guojian Pharmaceutical Co., Ltd. - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. - Shanghai Guosheng Pharmaceutical Co., Ltd. - Shanghai Lansheng States Kin Pharmaceutical Co., Ltd. - Shanghai Medipharm Biotech Co., Ltd. - Shanghai Zhangjiang Biotech Co., Ltd. - Shenzhen Main Luck Pharmaceuticals Inc. - Yunnan Walvax Biotechnology Co., Ltd. - Zhejiang Hisun Pharmaceutical Co., Ltd.
For more information visit
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets